High quality waveguides for the mid-infrared wavelength range in a silicon-on-sapphire platform

We report record low loss silicon-on-sapphire nanowires for applications to mid infrared optics. We achieve propagation losses as low as 0.8dB/cm at 1550nm, 1.1 to 1.4dB/cm at 2080nm and < 2dB/cm at = 5.18 microns.Comment: 9 pages, 6 figures, 18 reference

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer

The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of CT antigen expression has not yet been reported in prostate cancer. MAGE-C2/CT-10 is a novel CT antigen. The objective of this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. 348 prostate carcinomas from consecutive radical prostatectomies, 29 castration-refractory prostate cancer, 46 metastases, and 45 benign hyperplasias were immunohistochemically analyzed for MAGE-C2/CT10 expression using tissue microarrays. Nuclear MAGE-C2/CT10 expression was identified in only 3.3% primary prostate carcinomas. MAGE-C2/CT10 protein expression was significantly more frequent in metastatic (16.3% positivity) and castration-resistant prostate cancer (17% positivity; p<0.001). Nuclear MAGE-C2/CT10 expression was identified as predictor of biochemical recurrence after radical prostatectomy (p = 0.015), which was independent of preoperative PSA, Gleason score, tumor stage, and surgical margin status in multivariate analysis (p<0.05). MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. Further, the results suggest MAGE-C2/CT10 as a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer

Devices with optical gain in silicon

A photonic device includes a silicon semiconductor based superlattice. The superlattice has a plurality of layers that form a plurality of repeating units. At least one of the layers in the repeating unit is an optically active layer with at least one species of rare earth ion

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

Hepatocellular Carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Current systemic therapies result only in modest benefits and new therapeutic options are critically needed. Some patients show promising clinical responses to immune checkpoint inhibitors, however, additional immunotherapeutic approaches, such as adoptive cell therapies (ACT), need to be developed. This review summarizes recent ACT studies and discusses the promise and obstacles of this approach. We further discuss ways of improving the efficacy of ACT in HCC including the use of combination therapies and locoregional delivery methods

Low propagation loss silicon-on-sapphire integrated waveguides for the mid-infrared

We report low loss silicon-on-sapphire nanowires for applications to mid infrared optics. We achieve propagation losses of < 1dB/cm at λ = 1550nm and < 2dB/cm at λ = 5.08 μm

Low propagation loss silicon-on-sapphire nanowires for the mid-IR

We report low loss silicon-on-sapphire nanowires for applications to mid infrared optics. We achieve propagation losses of <1dB/cm at λ 1550nm, <1.5dB/cm at λ=2080nm and <2dB/cm at λ5.08 μm

Midinfrared supercontinuum generation from 2 to 6 μm in a silicon nanowire

Silicon has attracted great interest as a platform for both linear and nonlinear integrated photonics for over 15 years. While its primary applications have been in the telecom window (near 1.5 μm), the capability of exploiting its full transparency win